1. Home
  2. ARRY vs VTYX Comparison

ARRY vs VTYX Comparison

Compare ARRY & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Array Technologies Inc.

ARRY

Array Technologies Inc.

HOLD

Current Price

$6.93

Market Cap

1.1B

Sector

Technology

ML Signal

HOLD

Logo Ventyx Biosciences Inc.

VTYX

Ventyx Biosciences Inc.

HOLD

Current Price

$13.99

Market Cap

990.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARRY
VTYX
Founded
1989
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
990.9M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
ARRY
VTYX
Price
$6.93
$13.99
Analyst Decision
Buy
Hold
Analyst Count
19
7
Target Price
$10.24
$13.50
AVG Volume (30 Days)
6.6M
3.8M
Earning Date
06-02-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
62.56
40.30
EPS
N/A
N/A
Revenue
$1,284,141,000.00
N/A
Revenue This Year
$16.03
N/A
Revenue Next Year
$7.79
N/A
P/E Ratio
N/A
N/A
Revenue Growth
40.22
N/A
52 Week Low
$3.76
$0.90
52 Week High
$12.23
$15.34

Technical Indicators

Market Signals
Indicator
ARRY
VTYX
Relative Strength Index (RSI) 33.08 72.58
Support Level $6.47 $13.89
Resistance Level $10.02 $14.07
Average True Range (ATR) 0.56 0.03
MACD -0.16 -0.11
Stochastic Oscillator 7.54 88.89

Price Performance

Historical Comparison
ARRY
VTYX

About ARRY Array Technologies Inc.

Array Technologies Inc manufacturer of ground-mounting systems used in solar energy projects. The company's segments include: the Array legacy operating segment (Array Legacy Operations) and the STI Operations operating segment (STI Operations). It derives maximum revenue from the Array legacy operating segment. Its product is an integrated system of steel supports, electric motors, gearboxes, and electronic controllers referred to as a single-axis tracker that moves solar panels throughout the day to maintain an optimal orientation to the sun, which increases their energy production. Geographically, the company's operations are in the United States, Australia, Spain, Brazil, and the rest of the world, with the United States deriving the majority of the revenue.

About VTYX Ventyx Biosciences Inc.

Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.

Share on Social Networks: